GSK and Sanofi promise 200m COVID-19 vaccines to international COVAX initiative
October 28, 2020Manufacturing and Production, Research and Development COVAX, COVID-19, GSK, Sanofi
Sanofi and GSK have committed 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility, a …
Novartis collaborates with Molecular Partners to develop therapies to use against COVID-19
October 28, 2020Research and Development
Novartis and Molecular Partners AG have announced that they will develop, commercialise and manufacture Molecular’s anti-COVID-19 DARPin programme, which consists …
US reserves 300,000 doses of Lilly’s COVID-19 treatment in $375 million deal
October 28, 2020Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Eli Lilly, US, pharma
The US Government has signed a $375 million deal with Eli Lilly to buy 300,000 700mg doses of bamlanivimab, its …
80% of COVID-19 patients in study were vitamin D-deficient
October 28, 2020Research and Development
New research has found that over 80% of COVID-19 patients in a recent study had a vitamin D deficiency. The …
Pharmafile.com’s weekly COVID-19 news round-up
October 28, 2020Research and Development
The coronavirus news this week focuses on clinical trials testing potential vaccines, with the University of Oxford and AstraZeneca stating …
The November 2020 issue of Pharmafocus is available to read free online now!
October 27, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Biden, Pharmafocus, Trump, UK, US election, brexit, pharma, remdesivir
The latest monthly edition of Pharmafocus is available to read for free online now!
Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis
October 27, 2020Manufacturing and Production Dupixent, Sanofi, pharma
Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …
Eli Lilly antibody treatment fails COVID-19 study
October 27, 2020Manufacturing and Production
The US Government is putting an early end to clinical trials testing Eli Lilly’s antibody drug in COVID-19 patients. The …
New trial to test if cancer drug can effectively treat hallucinations in Parkinson’s patients
October 27, 2020Manufacturing and Production Parkinson's, Parkinson's UK
A new study is set to go ahead that will test if ondansetron is safe and effective in treating Parkinson’s …
US could have avoided over 130,000 COVID-19 deaths, according to a new study
October 27, 2020Manufacturing and Production COVID, COVID-19, Trump, coronavirus
New studies suggest that the US could have avoided over 130,000 deaths if it responded earlier and in a coordinated …
Bayer buys out US-based Asklepios BioPharmaceutical in potential $4bn deal
October 26, 2020Sales and Marketing Asklepios, Bayer, acquisition, pharma
Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical …
AstraZeneca’s COVID-19 vaccine generates immune response in both old and young participants
October 26, 2020Research and Development, Sales and Marketing AstraZeneca, COVID-19, University of Oxford, Vaccine
AstraZeneca’s much-hyped COVID-19 vaccine candidate, AZD1222, currently in development in partnership with the University of Oxford, has shown promising immune …
Novartis announces positive Phase 2 data of rare renal disease therapy iptacopan
October 26, 2020Sales and Marketing
Novartis has announced positive Phase 2 interim analysis results for iptacopan, which is an investigational oral treatment for rare renal …
UK Government outlines steps to tackle growing misuse of fentanyl
October 26, 2020Sales and Marketing
The British Government has responded to a report investigating the misuse of fentanyl and painkillers in the UK. In January …
WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19
October 26, 2020Sales and Marketing COVID, COVID-19, Gilead, coronavirus
The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir …
Patient Experience: Living with Timothy syndrome
October 26, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Timoty syndrome, feature, patient experience, rare disease
Thirteen-year-old Calvin Muir lives with the ultra-rare genetic condition Timothy syndrome. Like many parents of rare disease patients, his mother …
IBM and Pfizer designing AI model to predict onset of neurological diseases
October 23, 2020Medical Communications
IBM has partnered with Pfizer to design an artificial intelligence model to predict the eventual onset of neurological diseases – …
FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
October 23, 2020Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir
The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …
Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis
October 23, 2020Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma
NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …
Three Ways to Speed Your GxP Validation without Risk
October 23, 2020Medical Communications, Research and Development
Computer system validation can often take months to complete. It typically involves infrastructure qualification (IQ), operational qualification (OQ), and performance …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
